인스메드 (INSM) 주가

인스메드(INSM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $120.62 (-2.71%), 시가총액 $23.39B, 52주 최저~최고 $66.02 ~ $211.41.

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and

핵심 지표

• 현재가: $120.62 (-2.71%)
• 시가총액: $23.39B
• 52주 최저~최고: $66.02 ~ $211.41
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

인스메드의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

인스메드 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.8095

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 33.03
• 순이익률: -1.44%
• 영업이익률: -0.65%

자주 묻는 질문